Molina Healthcare, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Jul 28, 2022 and accepted by EDGAR at Jul 28, 2022, 10:33 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $8.05bn | us-gaap:Revenues |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $15.82bn | us-gaap:Revenues |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $6.87bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $13.44bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months2022-04-01 to 2022-06-30 | $361.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | $733.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $27.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $55.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $86.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $172.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | $248.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | $506.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | $4.25 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | $8.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | $4.29 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | $8.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 58,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 58,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | $731.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $50.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2022-01-01 to 2022-06-30 | $200.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-06-30 | $4.31bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $10.33bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $12.57bn | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $7.22bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $9.74bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $2.17bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2022-06-30 | $2.83bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001179929-22-000112. Last ingested by Listed: Nov 6, 2026, 17:05 ET. Listed shows no prices and gives no investment advice.